FDA: Page
-
Deep Dive
Biosimilars Council chief answers 6 key questions about biosims in the US
Dr. Bert Liang spoke with us to answer questions about the rapid pace of developments as biosimilars become a permanent part of healthcare in America.
By Nicole Gray • Sept. 2, 2015 -
Pharma takes major offense to French law promoting off-label Avastin use
France allows off-label use of Roche's Avastin (bevacizumab) for age-related macular degeneration (AMD), and the industry doesn't like it.
By Nicole Gray • Sept. 2, 2015 -
Alexion wins EU nod for newly acquired enzyme-replacement drug
Less than three months after completing the $8.4 billion acquisition of Synageva Biopharma, Alexion got an approval for Kanuma.
By Nicole Gray • Sept. 2, 2015 -
Pharma lobbies Congress for big—and expensive—changes to patent rules
According to the Congressional Budget Office (CBO), Inter Partes Review (IPR) exemptions being pursued by the industry could cost Medicare $1.3 billion over the next decade.
By Nicole Gray • Sept. 2, 2015 -
How do you solve a problem like drug shortages?
In 2011, there were 251 new drug shortages. That number has dwindled significantly—but there's still work to be done.
By Nicole Gray • Aug. 31, 2015 -
FDA warns: DPP-4 inhibiting diabetes meds may cause severe joint pain
The DDP-4 class includes major drugs from Merck, AstraZeneca, and Lilly/BI.
By Nicole Gray • Aug. 31, 2015 -
FDA's new draft guidance on naming biosimilars already drawing pushback
One main goal of the guidance is to prevent inadvertent substitution of non-interchangeable products.
By Nicole Gray • Aug. 28, 2015 -
Lilly/BI snag another FDA approval for a diabetes drug—Synjardy
This is the fifth FDA approval for the Eli Lilly/Boehringer Ingelheim Diabetes Alliance.
By Nicole Gray • Aug. 28, 2015 -
FDA demands another study for uniQure's ultra-pricey gene therapy
Glybera has courted its fair share of controversy.
By Nicole Gray • Aug. 27, 2015 -
J&J/Genmab unveil promising data for a potential multiple myeloma superstar
Daratumumab made waves at the American Society of Clinical Oncology meeting earlier this summer.
By Nicole Gray • Aug. 27, 2015 -
FTC to FDA: Ramp up oversight on homeopathic drug makers
The trade regulatory agency points out that many of the advertising claims from homeopathic drug makers are not evidence-based.
By Nicole Gray • Aug. 27, 2015 -
Deep Dive
Pfenex at the forefront: How a different biosim approach is becoming a disruptive force
We spoke with Dr. Bert Liang, Chairman of the Biosimilars Council and CEO of Pfenex, Inc., about the rapidly growing biosimilars industry in the U.S., and what comes next for Pfenex.
By Nicole Gray • Aug. 27, 2015 -
Sarepta wins priority review for hotly anticipated Duchenne drug
The target action date for Sarpeta's eteplirsen, a candidate for treatment of Duchenne muscular dystrophy, is February 26, 2016.
By Nicole Gray • Aug. 26, 2015 -
How Japan is trying to beef up its pharmaceutical industry
One proposed tactic is raising government-set drug prices to spur more innovation in R&D.
By Nicole Gray • Aug. 26, 2015 -
UK's NHS commissions new TB drugs for first time in 50 years
In the wake of drug-resistant TB, the NHS is taking action.
By Nicole Gray • Aug. 26, 2015 -
Sarepta, Biomarin vie for DMD approval, priority review voucher
Both companies are developing drugs for the rare pediatric disease Duchenne muscular dystrophy (DMD).
By Nicole Gray • Aug. 24, 2015 -
AbbVie snaps up priority review voucher from United Therapeutics for $350M
The pharma giant now has two priority review vouchers in its arsenal.
By Nicole Gray • Aug. 19, 2015 -
Merck star Keytruda nabs priority review for first-line treatment of metastatic melanoma
The treatment is currently indicated for secondary treatment of the cancer.
By Nicole Gray • Aug. 18, 2015 -
UPDATE: Sprout plots hiring binge after controversial female libido drug approval
Addyi has finally won a controversial FDA approval, and the drug's maker is already plotting big hiring plans. The drug's label comes with some strong warnings, and Sprout's marketing tactics are sure to be scrutinized.
By Nicole Gray , Sy Mukherjee • Aug. 18, 2015 -
Lawmakers set their sights on Valeant and its steep heart drug price hikes
Two high-profile lawmakers want to know why Valeant's newly acquired heart drugs, Isuprel and Nitropress, have increased by more than 300% in price.
By Nicole Gray • Aug. 17, 2015 -
FDA approves OxyContin use in some children
Doctors had already been prescribing the medication off-label for years.
By Nicole Gray • Aug. 17, 2015 -
Soaring drug costs at heart of military funding scuffle
The White House and some legislators want to increase military retirees' and families' co-pays over a 10-year period to help address soaring brand name and compound drug spending.
By Sy Mukherjee • Aug. 13, 2015 -
FDA chastizes Duchesnay, Kim Kardashian over drug promo posts
The reality star and model has been promoting a morning sickness drug during her pregnancy. But regulators say her social media posts don't disclose all the relevant details.
By Sy Mukherjee • Aug. 12, 2015 -
Armed with stronger label, can Sanofi's Toujeo perform better in the UK?
The drug is a successor to the company's flagship Lantus, which went off patent in March.
By Nicole Gray • Aug. 6, 2015 -
FDA to update Novartis' Gilenya label with brain-infection risk warning
The therapy is used to treat relapsing multiple sclerosis (RMS).
By Nicole Gray • Aug. 5, 2015